2012
2011
- Sept 12, 2011 - HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
- Apr 25, 2011 - HemaQuest Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
2010
- Dec 7, 2010 - HemaQuest Presents Promising Clinical Results at ASH 2010
- Dec 3, 2010 - HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
- Aug 11, 2010 - HemaQuest Pharmaceuticals Initiates Phase 2 Clinical Trial in EBV-Related Malignancies
- Jul 28, 2010 - HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
- Apr 21, 2010 - HemaQuest Pharmaceuticals Secures $12M to Advance Clinical Programs
2009
- Dec 8, 2009 - HemaQuest Pharmaceuticals Presents Promising Results in Sickle Cell Disease and Beta Thalassemia
- May 26, 2009 - HemaQuest Initiates Clinical Trials in Sickle Cell Disease and Beta Thalassemia
- Mar 25, 2009 - (EUROPE) Orphan Medicinal Product Designations for Therapeutic to Treat Hemoglobin Disorders
2008
- Dec 09, 2008 - Announcing Clinical Progress on New Sickle Cell Anemia Drug
- Nov 04, 2008 - (U.S.) Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
- Jan 17, 2008 - Phase 1 Clinical Trial of HQK-1001
2007
